DMD THERAPEUTICS
DMD Therapeutics Inc. operates as a biotechnology company. The company was incorporated in 2015 and is based in Seattle, Washington.
DMD THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Seattle, Washington, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
400 K USD
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Current Employees Featured
Founder
Investors List
Michael’s Cause
Michael’s Cause investment in Seed Round - DMD Therapeutics
Ryan’s Quest
Ryan’s Quest investment in Seed Round - DMD Therapeutics
Pietro’s Fight
Pietro’s Fight investment in Seed Round - DMD Therapeutics
More informations about "DMD Therapeutics"
NCATS Enables a Drug’s Path to FDA Approval for …
Mar 15, 2024 It became the first DMD therapy approved by both agencies. DMD is a rare, inherited, often devastating disease that weakens muscles. More than a decade ago, a Rockville, MD-based company, ReveraGen BioPharma Inc., …See details»
Cure Duchenne Muscular Dystrophy – CureDuchenne
With pioneering education and support programs, our organization drives real change for those with living with the disease and their loved ones. The CureDuchenne one-to-one program provides meetings with our ... (DMD) is …See details»
Therapeutic approaches for Duchenne muscular dystrophy
Aug 31, 2023 Duchenne muscular dystrophy (DMD) is a monogenic muscle-wasting disorder and a priority candidate for molecular and cellular therapeutics. Although rare, it is the most …See details»
FDA Expands Approval of Gene Therapy for Patients with …
Jun 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular …See details»
FDA Approves First Gene Therapy for Treatment of Certain …
Jun 23, 2023 FDA Approves Elevidys, a gene therapy for the treatment of pediatric patients 4 through 5 years of age with Duchenne muscular dystrophy (DMD) with a confirmed mutation in …See details»
FDA Approves First Gene Therapy for Duchenne …
For decades, doctors and researchers have been working diligently to discover new treatments and provide more options for patients with Duchenne muscular dystrophy (DMD), a debilitating genetic disease that ravages the muscles in …See details»
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The …
If there is one lesson from the eteplirsen saga for drug developers, it is that clinical development always should be rigorous and well controlled, and that working with the FDA in a constructive …See details»
Evolving Therapeutic Options for the Treatment of Duchenne …
Sep 6, 2023 Duchenne muscular dystrophy (DMD) is the most common childhood form of muscular dystrophy. It is caused by mutations in the DMD gene, leading to reduced or absent …See details»
Gene therapy for Duchenne muscular dystrophy: an update on the …
Aug 21, 2023 Most of these therapies have only a modest capability to restore the dystrophin or improve muscle function, suggesting an important unmet need in the development of DMD …See details»
FDA approves first gene therapy for Duchenne …
Jun 23, 2023 The FDA has granted accelerated approval to Sarepta’s gene therapy delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy (DMD). It is the first time the FDA has greenlit a gene ...See details»
Duchenne Muscular Dystrophy - StatPearls - NCBI …
Jul 10, 2023 Duchenne muscular dystrophy (DMD) is one of the most severe forms of inherited muscular dystrophies. It is the most common hereditary neuromuscular disease and does not exhibit a predilection for any race or …See details»
Experimental Gene Therapy Targets Duchenne Muscular Dystrophy
Feb 9, 2022 URMC was recently one of the first three sites in the nation to start dosing patients in a phase 3 placebo-controlled clinical trial for a gene therapy being developed by Sarepta …See details»
Emerging therapies for Duchenne muscular dystrophy
Jul 15, 2022 Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional dystrophin in the muscle cells. Major advances have led to the development of gene …See details»
Therapeutic developments for Duchenne muscular dystrophy
May 30, 2019 Duchenne muscular dystrophy (DMD) is caused by the lack of functional dystrophin protein. ... An overview of recent therapeutics advances for Duchenne muscular …See details»
Duchenne Muscular Dystrophy (DMD) | Sarepta Therapeutics
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne …See details»
Duchenne muscular dystrophy: disease mechanism and …
Pre-clinical results with the small molecule drug Ezutromid led Summit Therapeutics to initiate clinical trials as a potential treatment for DMD and BMD. Promising results from a Phase 1 …See details»
Developing DMD therapeutics: a review of the effectiveness of …
Jan 6, 2021 We review developments in four key areas of investigational DMD therapeutics:1. steroids and small molecules, 2. stop codon readthrough, 3. dystrophin gene replacement …See details»
DMD Therapeutics - Crunchbase Company Profile & Funding
Organization. DMD Therapeutics . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. About. DMD Therapeutics intends to use the funds to …See details»
New gene therapy for muscular dystrophy offers hope
Jul 17, 2024 A new gene therapy treatment for Duchenne muscular dystrophy (DMD) shows promise of not only arresting the decline of the muscles of those affected by this inherited …See details»
Characteristics of Patients Receiving Novel Muscular Dystrophy …
Jan 24, 2024 The US Food and Drug Administration (FDA) granted accelerated approval in 2016 for eteplirsen (Exondys 51; Sarepta Therapeutics), an antisense oligonucleotide therapy …See details»